{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:58:03Z","timestamp":1744520283003},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00105-020-04604-4","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T18:03:31Z","timestamp":1589306611000},"page":"518-524","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Moderne systemische Therapie des Pruritus"],"prefix":"10.1007","volume":"71","author":[{"given":"M.","family":"Metz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"10","key":"4604_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2340\/00015555-3243","volume":"99","author":"ZZ Almustafa","year":"2019","unstructured":"Almustafa\u00a0ZZ, Weller\u00a0K, Autenrieth\u00a0J et\u00a0al (2019) Dupilumab in treatment of chronic Prurigo: a case series and literature review. Acta Derm Venereol 99(10):905\u2013906","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"4604_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","volume":"141","author":"IS Bagci","year":"2018","unstructured":"Bagci\u00a0IS, Ruzicka\u00a0T (2018) IL-31: A new key player in dermatology and beyond. J\u00a0Allergy Clin Immunol 141(3):858\u2013866","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4604_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","volume":"123","author":"NV Bergasa","year":"1995","unstructured":"Bergasa\u00a0NV, Alling\u00a0DW, Talbot\u00a0TL et al (1995) Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123(3):161\u2013167","journal-title":"Ann Intern Med"},{"issue":"2","key":"4604_CR4","doi-asserted-by":"publisher","first-page":"adv00027","DOI":"10.2340\/00015555-3347","volume":"100","author":"E Fowler","year":"2020","unstructured":"Fowler\u00a0E, Yosipovitch\u00a0G (2020) A new generation of treatments for itch. Acta Derm Venereol 100(2):adv27","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"4604_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaci.2016.12.960","volume":"140","author":"T Fukuyama","year":"2017","unstructured":"Fukuyama\u00a0T, Ganchingco\u00a0JR, Mishra\u00a0SK et al (2017) Janus kinase inhibitors display broad anti-itch properties: a possible link through the TRPV1 receptor. J\u00a0Allergy Clin Immunol 140(1):306\u2013309.e3","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"4604_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay\u00a0RJ, Johns\u00a0NE, Williams\u00a0HC et\u00a0al (2014) The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J\u00a0Invest Dermatol 134(6):1527\u20131534","journal-title":"J Invest Dermatol"},{"issue":"7","key":"4604_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrn1950","volume":"7","author":"A Ikoma","year":"2006","unstructured":"Ikoma\u00a0A, Steinhoff\u00a0M, St\u00e4nder\u00a0S et\u00a0al (2006) The neurobiology of itch. Nat Rev Neurosci 7(7):535\u2013547","journal-title":"Nat Rev Neurosci"},{"key":"4604_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030073","author":"R Khanna","year":"2019","unstructured":"Khanna R, Boozalis E (2019) Mirtazapine for the treatment of chronic pruritus. Medicines. https:\/\/doi.org\/10.3390\/medicines6030073","journal-title":"Medicines"},{"issue":"12","key":"4604_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/exd.14024","volume":"28","author":"AE Kremer","year":"2019","unstructured":"Kremer\u00a0AE (2019) What are new treatment concepts in systemic itch? Exp Dermatol 28(12):1485\u20131492","journal-title":"Exp Dermatol"},{"key":"4604_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","volume":"338","author":"M Kremer","year":"2016","unstructured":"Kremer\u00a0M, Salvat\u00a0E, Muller\u00a0A et\u00a0al (2016) Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience 338:183\u2013206","journal-title":"Neuroscience"},{"issue":"10","key":"4604_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada\u00a0H, Miyakawa\u00a0H, Muramatsu\u00a0T et al (2017) Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res 47(10):972\u2013982","journal-title":"Hepatol Res"},{"issue":"4","key":"4604_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai\u00a0H, Ebata\u00a0T, Takamori\u00a0K et al (2010) Effect of a\u00a0novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a\u00a0Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25(4):1251\u20131257","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"4604_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1468-3083.2009.03129.x","volume":"23","author":"F Malekzad","year":"2009","unstructured":"Malekzad\u00a0F, Arbabi\u00a0M, Mohtasham\u00a0N et al (2009) Efficacy of oral naltrexone on pruritus in atopic eczema: a\u00a0double-blind, placebo-controlled study. J\u00a0Eur Acad Dermatol Venereol 23(8):948\u2013950","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4604_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000484573","volume":"46","author":"VS Mathur","year":"2017","unstructured":"Mathur\u00a0VS, Kumar\u00a0J, Crawford\u00a0PW et al (2017) A multicenter, randomized, double-blind, placebo-controlled trial of Nalbuphine ER tablets for uremic pruritus. Am J Nephrol 46(6):450\u2013458","journal-title":"Am J Nephrol"},{"issue":"6","key":"4604_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2340\/00015555-1159","volume":"91","author":"U Matterne","year":"2011","unstructured":"Matterne\u00a0U, Apfelbacher\u00a0CJ, Loerbroks\u00a0A et al (2011) Prevalence, correlates and characteristics of chronic pruritus: a\u00a0population-based cross-sectional study. Acta Derm Venereol 91(6):674\u2013679","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"4604_CR16","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/exd.14007","volume":"28","author":"M Metz","year":"2019","unstructured":"Metz\u00a0M (2019) Treatments for chronic pruritus outside of the box. Exp Dermatol 28(12):1476\u20131481","journal-title":"Exp Dermatol"},{"key":"4604_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.056","author":"DM Pariser","year":"2020","unstructured":"Pariser\u00a0DM, Bagel\u00a0J, Lebwohl\u00a0M et al (2020) Serlopitant for psoriatic pruritus: a\u00a0phase 2 randomized, double-blind, placebo-controlled clinical trial. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.056","journal-title":"J Am Acad Dermatol"},{"issue":"9041","key":"4604_CR18","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","volume":"348","author":"G Peer","year":"1996","unstructured":"Peer\u00a0G, Kivity\u00a0S, Agami\u00a0O et\u00a0al (1996) Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348(9041):1552\u20131554","journal-title":"Lancet"},{"issue":"9","key":"4604_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40265-017-0746-9","volume":"77","author":"MP Pereira","year":"2017","unstructured":"Pereira\u00a0MP, St\u00e4nder\u00a0S (2017) Chronic Pruritus: current and emerging treatment options. Drugs 77(9):999\u20131007","journal-title":"Drugs"},{"issue":"12","key":"4604_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/13543784.2018.1548606","volume":"27","author":"MP Pereira","year":"2018","unstructured":"Pereira\u00a0MP, St\u00e4nder\u00a0S (2018) Novel drugs for the treatment of chronic pruritus. Expert Opin Investig Drugs 27(12):981\u2013988","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"4604_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","volume":"63","author":"NQ Phan","year":"2010","unstructured":"Phan\u00a0NQ, Bernhard\u00a0JD, Luger\u00a0TA et al (2010) Antipruritic treatment with systemic mu-opioid receptor antagonists: a\u00a0review. J\u00a0Am Acad Dermatol 63(4):680\u2013688","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4604_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2340\/00015555-1353","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan\u00a0NQ, Lotts\u00a0T, Antal\u00a0A et\u00a0al (2012) Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a\u00a0literature review. Acta Derm Venereol 92(5):555\u2013560","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"4604_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s00105-009-1730-4","volume":"60","author":"S Schulz","year":"2009","unstructured":"Schulz\u00a0S, Metz\u00a0M, Siepmann\u00a0D et al (2009) Antipruritic efficacy of a\u00a0high-dosage antihistamine therapy. Results of a\u00a0retrospectively analysed case series. Hautarzt 60(7):564\u2013568","journal-title":"Hautarzt"},{"issue":"24","key":"4604_CR24","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson\u00a0EL, Bieber\u00a0T, Guttman-Yassky\u00a0E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N\u00a0Engl J Med 375(24):2335\u20132348","journal-title":"N Engl J Med"},{"issue":"5","key":"4604_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","volume":"80","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder\u00a0S, Kwon\u00a0P, Hirman\u00a0J et al (2019) Serlopitant reduced pruritus in patients with prurigo nodularis in a\u00a0phase 2, randomized, placebo-controlled trial. J\u00a0Am Acad Dermatol 80(5):1395\u20131402","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4604_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bjd.18025","volume":"181","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder\u00a0S, Yosipovitch\u00a0G (2019) Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Br J Dermatol 181(5):932\u2013938","journal-title":"Br J Dermatol."},{"issue":"8","key":"4604_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S, Yosipovitch\u00a0G, Legat\u00a0FJ et al (2020) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N\u00a0Engl J Med 382(8):706\u2013716","journal-title":"N Engl J Med"},{"issue":"8","key":"4604_CR28","first-page":"860","volume":"15","author":"S St\u00e4nder","year":"2017","unstructured":"St\u00e4nder\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et al (2017) S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus \u2013 Update \u2013 Kurzversion. J\u00a0Dtsch Dermatol Ges 15(8):860\u2013873","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"4604_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjd.15905","volume":"178","author":"A Tsianakas","year":"2018","unstructured":"Tsianakas\u00a0A, Luger\u00a0TA, Radin\u00a0A (2018) Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a\u00a0randomized, placebo-controlled clinical trial. Br J Dermatol 178(2):406\u2013414","journal-title":"Br J Dermatol"},{"issue":"4","key":"4604_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2340\/00015555-3120","volume":"99","author":"A Tsianakas","year":"2019","unstructured":"Tsianakas\u00a0A, Zeidler\u00a0C, Riepe\u00a0C et al (2019) Aprepitant in anti-histamine-refractory chronic nodular Prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II trial (APREPRU). Acta Derm Venereol 99(4):379\u2013385","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"4604_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2340\/00015555-3164","volume":"99","author":"E Weisshaar","year":"2019","unstructured":"Weisshaar\u00a0E, Szepietowski\u00a0JC, Dalgard\u00a0FJ et\u00a0al (2019) European S2k guideline on chronic Pruritus. Acta Derm Venereol 99(5):469\u2013506","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"4604_CR32","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1681\/ASN.2005020152","volume":"16","author":"B Wikstrom","year":"2005","unstructured":"Wikstrom\u00a0B, Gellert\u00a0R, Ladefoged\u00a0SD et al (2005) Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J\u00a0Am Soc Nephrol 16(12):3742\u20133747","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4604_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/14712598.2020.1722998","volume":"20","author":"J Wu","year":"2020","unstructured":"Wu J, Guttman-Yassky E (2020) Efficacy of biologics in atopic dermatitis. Expert Opin Biol Ther 20(5):525\u2013538","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"4604_CR34","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","volume":"78","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch\u00a0G, St\u00e4nder\u00a0S, Kerby\u00a0MB et al (2018) Serlopitant for the treatment of chronic pruritus: Results of a\u00a0randomized, multicenter, placebo-controlled phase 2 clinical trial. J\u00a0Am Acad Dermatol 78(5):882\u2013891.e10","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"4604_CR35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","volume":"73","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier\u00a0T, Aberer\u00a0W, Asero\u00a0R (2018) The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73(7):1393\u20131414","journal-title":"Allergy"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04604-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:16:31Z","timestamp":1620774991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04604-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4604"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04604-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"12 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Metz und M.P.\u00a0Pereira geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}